Table 1.
Summary of resistance mutations selected during successful therapy
| Pt. | Previous drugs* | Current drugs* | Baseline mutations† | Clone no. | New mutations† (Clone no.) |
|---|---|---|---|---|---|
| Analyzed by molecular cloning | |||||
| M | ZDV | ZDV + 3TC + IDV | RT 41L, 44D, 67N, 70R, 215Y | 42 | RT 118I (3) |
| C | ZDV | ZDV + 3TC + IDV | RT 67N, 70R, 219Q | 98 | PR 54V; RT 184V (2) |
| K | ddI, ZDV | ZDV + 3TC + IDV | PR {71V}; RT 41L, 74V, 215Y | 39 | PR 46I, 77I; RT 118I, 210W (2) |
| L | ZDV | ZDV + 3TC + IDV | RT 67N, 219Q | 26 | PR 46V, I;RT 69D, 70R (6) |
| A | ZDV | ZDV + 3TC + IDV | RT 70R | 17 | None |
| B | ZDV | ZDV + 3TC + IDV | RT 70R | 36 | None |
| Analyzed by biological cloning | |||||
| 9 | RTV, RTV + ZDV | DV + 3TC + RTV + SQ | Gag (p7p1)V; PR 54V, 77I, 82A; RT 70R (on-HAART) | 65 (6 times) | PR {10I, 71V}, 90M (6) |
| 11 | None | d4T + RTV + SQV | – | 4 | None |
| 23 | None | ZDV + 3TC + IDV | – | 16 | None |
| 24 | None | ZDV + 3TC + NFV | – | 12 | None |
*
ZDV, zidovudine; 3TC, lamivudine; IDV, indinavir; RTV, ritonavir; SQV, saquinavir; d4T, stavudine; and NFV, nelfinavir.
†
Baseline resistance mutations were identified in ref. 1. New on-therapy resistance mutations selected by drugs given only during the current successful regimen are in bold: lamivudine selected (italics and bold) and protease inhibitor selected (bold, not italicized). Brackets signify natural polymorphisms, which may also be drug-selected. Each position was not interrogated in every clone.